Want to see FHTX full AI Analyst Report?
Foghorn Therapeutics (FHTX) AI Stock Analysis
Foghorn Therapeutics
(NASDAQ:FHTX)
The score is held down primarily by weak financial performance—large ongoing losses, negative equity, and significant cash burn—combined with very bearish technicals (price well below major moving averages and negative momentum). Valuation provides limited support due to losses (negative P/E) and no dividend, while corporate events are mixed: a discontinued collaboration program is a setback, partially offset by cost cuts aimed at extending runway.
Foghorn Therapeutics (FHTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $113.13M
- Dividend Yield
- ―
- Average Volume (3M)
- 760.93K
- Price to Earnings (P/E)
- -1.9
- Beta (1Y)
- 1.74
- Revenue Growth
- 51.98%
- EPS Growth
- 17.68%
- Country
- US
- Employees
- 106
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Foghorn Therapeutics Business Overview & Revenue Model
Company Description
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs...
How the Company Makes Money
Foghorn Therapeutics does not primarily generate revenue from commercial product sales because it is a clinical-stage company and, to the extent publicly disclosed, has no approved products on the market. Its revenue, when reported, is primarily deri...
Foghorn Therapeutics Financial Statement Overview
Summary
Despite ~30% TTM revenue growth to ~$36.7M, the company remains deeply unprofitable (TTM net loss ~-$64.6M; net margin ~-267%) with TTM gross profit turning slightly negative. Balance-sheet risk is elevated due to negative stockholders’ equity (~-$81.0M TTM) alongside meaningful debt (~$43.1M), and cash burn is heavy (TTM operating cash flow ~-$84.2M; free cash flow ~-$84.3M), implying continued dependence on external funding.
Income Statement
23NegativeBalance Sheet
18Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.74M | 30.91M | 22.60M | 34.16M | 19.23M | 1.32M |
| Gross Profit | 15.70M | 27.58M | 22.60M | 34.16M | 19.23M | 1.32M |
| EBITDA | -62.46M | -70.95M | -97.17M | -90.75M | -105.56M | -96.19M |
| Net Income | -64.58M | -74.28M | -86.62M | -98.43M | -108.88M | -101.32M |
Balance Sheet | ||||||
| Total Assets | 203.39M | 198.10M | 283.98M | 285.92M | 404.88M | 519.77M |
| Cash, Cash Equivalents and Short-Term Investments | 167.58M | 158.89M | 243.75M | 234.06M | 345.80M | 154.29M |
| Total Debt | 43.10M | 41.27M | 37.13M | 45.07M | 51.51M | 58.33M |
| Total Liabilities | 284.43M | 306.60M | 329.51M | 363.11M | 404.77M | 422.90M |
| Stockholders Equity | -81.04M | -108.50M | -45.53M | -77.19M | 112.00K | 96.87M |
Cash Flow | ||||||
| Free Cash Flow | -85.35M | -86.15M | -101.31M | -119.33M | 192.40M | -53.56M |
| Operating Cash Flow | -85.30M | -86.10M | -100.41M | -118.11M | 193.61M | -50.25M |
| Investing Cash Flow | 28.12M | 112.04M | -29.90M | 144.45M | -244.32M | 36.17M |
| Financing Cash Flow | 608.00K | 1.02M | 105.43M | 1.78M | 1.76M | 22.42M |
Foghorn Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FHTX, the sentiment is Negative. The current price of 1.91 is below the 20-day moving average (MA) of 2.00, below the 50-day MA of 3.22, and below the 200-day MA of 4.63, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 26.78 is Positive, neither overbought nor oversold. The STOCH value of 49.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FHTX.
Foghorn Therapeutics Risk Analysis
Foghorn Therapeutics disclosed 54 risk factors in its most recent earnings report. Foghorn Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskFoghorn Therapeutics Peers Comparison
Overall Rating
FULC51Neutral
CCCC45Neutral
ALXO42Neutral- FHTX42Neutral
ZNTL40Underperform
KPTI39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FULC | 51Neutral | $287.64M | -3.04 | -28.54% | ― | ― | 0.04% |
| CCCC | 45Neutral | $383.84M | -4.10 | -37.71% | ― | 2.33% | 36.86% |
| ALXO | 42Neutral | $188.06M | -1.02 | -90.30% | ― | ― | 48.20% |
| FHTX | 42Neutral | $124.71M | -1.92 | 72.64% | ― | 51.98% | 17.68% |
| ZNTL | 40Underperform | $166.62M | -0.69 | -87.95% | ― | -100.00% | 14.08% |
| KPTI | 39Underperform | $1.65M | -0.00 | 77.63% | ― | 6.81% | 11.95% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FHTX | Foghorn Therapeutics, Inc. | 1.91 | -2.46 | -56.31% | |
| KPTI | Karyopharm Therapeutics INC | 0.06 | -5.10 | -98.84% | |
| FULC | Fulcrum Therapeutics | 3.68 | -3.95 | -51.77% | |
| ZNTL | Zentalis Pharmaceuticals Inc | 1.71 | 0.43 | 33.59% | |
| ALXO | Alx Oncology Holdings, Inc. | 1.15 | -0.23 | -16.67% | |
| CCCC | C4 Therapeutics, Inc. | 2.95 | 0.61 | 26.07% |
Foghorn Therapeutics Corporate Events
Foghorn Therapeutics Announces Major Strategic Reprioritization, Layoffs
NegativeOn September 25, 2026, Foghorn Therapeutics and Eli Lilly decided not to advance FHD-909, a Phase 1 SMARCA2-targeting program, into the expansion phase and ended further collaboration activities, after the SMARCA2/4 synthetic lethality strategy faile...
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress
PositiveOn August 6, 2026, Foghorn Therapeutics reported second-quarter 2026 results and a corporate update, highlighting progress across its oncology and immunology pipeline and collaboration with Eli Lilly. The company’s Phase 1 trial of SMARCA2 inhi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026